Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23846023 | 1.00 | NR3C1 (0.38) | NR3C1CA12CA1CA2CA4 | |
| SCHEMBL23961616 | 1.00 | NR3C1 (0.38) | NR3C1CA12CA1CA2CA4 | |
| SCHEMBL19026314 | 0.93 | CA12 (0.36) | NR3C1CA12CA1CA2CA4 | |
| SCHEMBL27432928 | 0.93 | NR3C1 (0.36) | NR3C1CA12CA1CA2CA4 | |
| SCHEMBL18019443 | 0.92 | NR3C1 (0.37) | NR3C1CA12CA1CA2CA4 | |
| SCHEMBL23071797 | 0.92 | NR3C1 (0.38) | NR3C1HTTFNTAFNTBMEN1 | |
| SCHEMBL22702676 | 0.92 | NR3C1 (0.38) | NR3C1HTTFNTAFNTBMEN1 | |
| SCHEMBL31045397 | 0.92 | NR3C1 (0.38) | NR3C1HTTFNTAFNTBMEN1 | |
| SCHEMBL19211630 | 0.91 | NR3C1 (0.37) | NR3C1CA12CA1CA2CA4 | |
| SCHEMBL16945805 | 0.91 | NR3C1 (0.38) | NR3C1CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR, S.A. (ES) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | HDGF, XPOT, TXLNA | NR3C1 3788/4885CA12 2973/4885CA1 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.